en
Proteolysis-targeting chimeras (PROTACs) degrade proteins, expanding therapeutic reach to undruggable targets while offering selectivity and efficacy. Their poor solubility, high polarity, and large size hinder bioavailability. This article outlines solid-form strategies—polymorph screening and salt/cocrystal optimization—to enhance solubility, stability, and developability in PROTAC drug development.
Subscribe to be the first to get the updates!
